Neil Kumar, BridgeBio CEO (Jeff Rumans for Endpoints News)
March 14, 2022 11:12 AM EDTUpdated 11:48 AM
R&D

Af­ter De­cem­ber tri­al fail, Bridge­Bio has good news from PhII for LGMD2i drug

Josh Sullivan

Bridge­Bio Phar­ma was in need of some good news. It got some from its Phase II tri­al of a drug for limb-gir­dle mus­cu­lar dy­s­tro­phy …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: CEO of Unit­ed­Health in­sur­ance unit shot and killed in New York in what po­lice call ‘a brazen, tar­get­ed ...

Lil­ly beats No­vo in bell­wether head-to-head weight loss study

As 23andMe strug­gles, an­oth­er ge­net­ic test­ing com­pa­ny bets on drug dis­cov­ery

GSK makes an­oth­er ADC deal, this time with BioN­Tech's part­ner Du­al­i­ty­Bio

Lil­ly drops body mass ranges from FDA la­bel for weight loss drug

Blue­bird and Ver­tex's sick­le cell gene ther­a­pies to kick off new Med­ic­aid ac­cess mod­el

A service from the Financial Times